Cequent Pharmaceuticals said this week that it has named Johannes Fruehauf as its director of preclinical and clinical development.
Fruehauf was previously a senior research fellow at Harvard Medical School’s Beth Israel Deaconess Medical Center. He holds an MD from the University of Heidelberg and is a co-developer of Cequent’s core transkingdom RNAi technology.
Cequent also said that it has appointed Jens Harborth as its associated director of RNAi research.
Harborth was previously a senior scientist at Alnylam Pharmaceuticals. He holds a PhD in biochemistry from Georg-August University.
Talyst, a pharmacy automation firm, has named Greg Weaver as its CFO.
Weaver was previously senior vice president and CFO of Sirna Therapeutics, which was acquired by Merck earlier this year.